Transplantation of angiogenin-overexpressing mesenchymal stem cells synergistically augments cardiac function in a porcine model of chronic ischemia  by Huang, Sheng-Dong et al.
T
m
f
S
X
Y
Huang et al Cardiopulmonary Support and Physiologyransplantation of angiogenin-overexpressing
esenchymal stem cells synergistically augments cardiac
unction in a porcine model of chronic ischemia
heng-Dong Huang, MD, PhD,a Fang-Lin Lu, MD, PhD,a Xun-Yu Xu, MD, PhD,a Xiao-Hong Liu, MD, PhD,a
ian-Xian Zhao, MD, PhD,b Bao-Zhen Zhao, MD, PhD,c Li Wang, MD, PhD,d De-Jun Gong, MD, PhD,aang Yuan, MD, PhD,a and Zhi-Yun Xu, MD, PhDa
O
d
m
a
f
M
c
w
w
c
A
f
w
s
R
A
f
d
g
A
a
c
c
C
w
p
C ium
m
s ight
e
r
i
n 45.
CS
PFrom the Institute of Thoracic Cardiac Sur-
gerya and the Departments of Cardiology,b
Ultrasound,c and Radiology,d Changhai
Hospital Second Military Medical Univer-
sity, Shanghai, People’s Republic of China.
Supported by the National Natural Science
Foundation of China (grant 30371418 and
30471718).
Received for publication May 12, 2006;
revisions received July 7, 2006
Address for reprints: Zhi-Yun Xu, MD,
PhD, Institute of Thoracic Cardiac Surgery,
Changhai Hospital, 174 Changhai Rd, Shang-
hai, 200433, People’s Republic of China
(E-mail: zhiyunxu@smmu.edu.cn).
J Thorac Cardiovasc Surg 2006;132:1329-38
0022-5223/$32.00
Copyright © 2006 by The American Asso-
ciation for Thoracic Surgery
Drs Huang and Xu (left to right).M
doi:10.1016/j.jtcvs.2006.08.021
Tbjective: Accumulated evidence suggests that myogenesis and angiogenesis in-
uced by implanted cells play important roles in restoring cardiac function after a
yocardial infarction. The current study investigated the effects of transplanted
utologous mesenchymal stem cells overexpressing angiogenin on myocardial per-
usion and cardiac function in the porcine chronic ischemic model.
ethods: Chronic ischemia was generated in Yorkshire pigs by placing an ameroid
onstrictor around the left circumflex artery. Four weeks after occlusion, the animals
ere randomly separated into 4 groups: pigs in the MSCAdAng or MSCAdNull groups
ere implanted with 6  108 mesenchymal stem cells infected with adenovirus
ontaining angiogenin gene or null adenovirus, respectively; pigs in the AdAng or
dNull groups were injected intramyocardially with adenovirus (5  109 plaque
orming unit/pig) containing angiogenin gene or null adenovirus, respectively. Four
eeks after implantation, mesenchymal stem cells prelabeled with DiI were ob-
erved within the implanted area in both cell transplantation groups.
esults: Angiogenin protein levels were significantly greater in the MSCAdAng and
dAng groups than in the other 2 groups and were associated with greater neovessel
ormation than in the other 2 groups. Mesenchymal stem cell transplantation
ecreased scar size and increased scar thickness. Both the AdAng and MSCAdNull
roups experienced improved cardiac function compared with that seen in the
dNull group. However, a synergistic effect of mesenchymal stem cells and
ngiogenin was observed in the MSCAdAng group because myocardial perfusion and
ardiac function increased significantly (P  .05 for all groups) in this group
ompared with all the others.
onclusions: Transplantation of autologous mesenchymal stem cells transfected
ith the angiogenin gene revealed a synergistic effect on the improvement of heart
erfusion and function after ameroid occlusion.
oronary occlusions can result in congestive heart failure if the heart cannot
mount an adequate angiogenic response to restore perfusion to the ischemic
cardiomyocytes. The implantation of cells into the ischemic myocard
ight restore function by inducing angiogenesis and preventing wall thinning and
car expansion.1-5 Augmentation of cell transplantation with proteins or genes m
nhance the regeneration achieved with this therapy. However, few studies have
eported a synergistic effect of cell and gene therapy on heart function in an
schemic cardiomyopathic model.
Mesenchymal stem cells (MSCs) possess pluripotential capabilities6 and are
egative for hematopoietic lineage cell markers, including CD34 and CD6,7
SCs are easily obtained from bone marrow and can be expanded in culture and
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CSPhen cryopreserved for future use.8-11 Encouraging preclin-
cal data have established the feasibility of autologous mar-
ow cell transplantation, and several clinical studies have
een initiated12,13 suggesting that MSCs might be the id
onor cells for cellular cardiomyoplasty.
Angiogenin is a basic heparin-binding protein of 14.4
 d that stimulates angiogenesis.14 We have successfully
pliced the human angiogenin gene into an adenovirus that
an increase vessel density when implanted into ischemic
earts.15,16 Transfection by means of direct injection of 
ene into the myocardial tissue is low, but transplanted cells
an alternatively be used as carriers for gene transfer. In this
ase cells were transfected in vitro with the angiogenin gene
o enhance gene expression after implantation into damaged
issue.
In the present study we directly compared the effects of
utologous MSC transplantation therapy and angiogenin
ene therapy, alone and in combination, on the restoration
f cardiac function in the ischemic heart in an adult pig
odel. By using clinically relevant evaluation techniques,
e showed that both cell therapy and gene therapy im-
roved cardiac function. However, the combination treat-
ent synergistically enhanced cardiac function. Our data
rovide important information concerning the potential clin-
cal application of genetically modified cell transplantation
o treat patients with ischemic heart disease.
aterials and Methods
xperimental Animals
orkshire pigs (20-25 kg) were obtained from Shanghai Experi-
ental Animal Supply, China. The animal protocol was approved
y the Institutional Animal Care and Utilization Committee of the
econd Military Medical University. All operative procedures
ere performed according to the “Canadian Council on Animal
are and Use of Laboratory Animals,” published by the National
Abbreviations and Acronyms
AdAng group  pigs injected with adenovirus
containing angiogenin
AdNull group  pigs injected with null adenovirus
DiI  1,1=-Dioctadecyl-3,3,3=,3=-
tetramethylindecarboxyanino
FAC  fractional area change
LV  left ventricular
LVEF  left ventricular ejection fraction
MRI magnetic resonance imaging
MSC mesenchymal stem cell
MSCAdAng group  pigs implanted with angiogenin-
transfected MSCs
MSCAdNull group pigs implanted with null
adenovirus-transfected MSCs
PFU  plaque forming unitnstitute of Health. w
330 The Journal of Thoracic and Cardiovascular Surgery ● Decnimal Model
porcine model of chronic myocardial ischemia was induced by
sing ameroid constrictors. Forty pigs were sedated with ketamine
ydrochloride (15 mg/kg administered intramuscularly) and anes-
hetized with pentobarbital sodium (10 mg/kg administered intra-
enously). The animals were then intubated and ventilated with
xygen containing isoflurane (0.8% to 1.5%). In each animal the
liac crest area was prepared by using sterile techniques, and
pproximately 14 mL of bone marrow was aspirated into a syringe
ontaining 6000 units of heparin for MSC isolation and culture.
A left thoracotomy was then performed, and an ameroid con-
trictor (2.25-2.50 mm diameter matched to the diameter of the
rtery; Research Instruments SW) was placed around the proximal
eft circumflex branch of the left coronary artery. The pericardium
nd the chest were closed. The animals were treated postopera-
ively with amoxicillin (500 mg administered orally twice daily)
nd buprenorphine (0.3 mg administered intramuscularly twice
aily) for 3 days.
solation and Expansion of MSCs
he bone marrow underwent gradient centrifugation. Mononuclear
ells were collected and cultured in cell culture media (DM-10)
upplemented with 1% penicillin-streptomycin and 10% fetal bo-
ine serum. The cells were incubated with antibodies against
D34 and CD45, and these cells were removed by passing through
magnetic column (Miltenyi Biotech). The CD34/CD45 MSCs
ere collected,7 cultured, and subcultured for transplantation.
ngiogenin Gene Transfection and Cell Labeling
eplication-deficient recombinant adenovirus containing the hu-
an angiogenin gene was constructed. One day before transplan-
ation, the MSCs were infected with the adenovirus at 50 plaque
orming unit (PFU)/cell. Null adenovirus was used to infect MSCs
s a control group. Some of the cultured MSCs were infected with
denovirus containing green fluorescence protein gene to examine
he transduction efficiency. On the day of implantation, the MSCs
ere also labeled with 1,1=-Dioctadecyl-3,3,3=,3=-tetramethylinde-
arboxyanino (DiI), according to the manufacturer’s protocol. The
abeled cells were washed, detached from the culture dish, centri-
uged, and suspended in culture media containing 1000 units of
eparin (6  108 cells/mL) for transplantation.
SC or Gene Implantation
our weeks after ameroid constrictor implantation, occlusion of
he target artery was confirmed by means of angiography. Forty
igs were randomly assigned to one of 4 experimental groups, as
ollows: group 1, 10 pigs implanted with angiogenin-transfected
SCs (MSCAdAng group; 6.0  108 cells per pig); group 2, 10 pigs
mplanted with null adenovirus-transfected MSCs (MSCAdNull
roup; 6.0  108 cells per pig); group 3, 10 pigs injected with
denovirus containing angiogenin (AdAng group, 5  109 PFU/
ig); and group 4, 10 pigs injected with null adenovirus (AdNull
roup, 5  109 PFU/pig). The cells or viral solutions were in-
ramyocardially injected with a 30-gauge needle at 9 locations
ithin the ischemic myocardial area through an open chest inci-
ion. After implantation, the chest was closed, and each animal
as recovered as previously described.
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Poronary Angiographic Analysis of Collateral Density
oronary angiography was performed before and 4 weeks after
ell or virus implantation to confirm occlusion and formation
f collateral vessels. After achievement of general anesthesia, a 7F
atheter (Britetip JL4 or Cordis) was inserted into the right coro-
ary artery. Contrast medium (4.5 mL) was injected at a rate of 1.5
L/s, and digitally subtracted images were obtained. These same
rocedures were repeated for the left coronary artery. Evaluation
f angiographic collateral density was performed through cine film
eviewed by 2 experienced angiographers who were blinded to the
xperimental groups by using a Rentrop score from 0 to 3 (0  no
isible collateral vessels; 1  faint filling of side branches of the
ain epicardial vessel without filling the main vessel; 2  partial
lling of the main epicardial vessel; 3  complete filling of the
ain vessel).17
chocardiographic Analysis of Regional and Global
eart Function
chocardiographic images (Hewlett Packard) were obtained in the
pen-chest state before and 4 weeks after treatment. Images were
ompared by using apical 4-chamber and midventricular short-axis
lanes. Left ventricular (LV) end-diastolic volume (EDV) and LV
nd-systolic volume (ESV) were measured, and LV ejection frac-
ion (LVEF) was calculated by using the following equation:
VEF  EDV  ESV  ⁄EDV  100%. Ventricular function was
lso evaluated as fractional area change (FAC) of the left ventricle.
AC was measured by tracing the end-diastolic area (EDA) and
he end-systolic area (ESA) of the ventricle from the midpapil-
ary short-axis view and then was calculated as follows: FAC 
EDA  ESA ⁄EDA  100%. Regional wall thickening was de-
ermined by measuring lateral-posterior wall thickness at end
iastole and end systole and using the following equation:
all thickening (Systolic thickness Diastolic thickness) ⁄
Systolic thickness 100% .
agnetic Resonance Imaging
agnetic resonance imaging (MRI) was performed before and 4
eeks after treatment. Each animal was sedated with ketamine
ydrochloride (5 mg/kg administered intramuscularly) and diaze-
am (10 mg per pig administered intramuscularly) and placed in a
rone position with a 4-channel, quadrature body, phased-array
oil positioned over the back. Basal, midventricular, and apical
mages were collected simultaneously. For perfusion analysis, the
V image was divided into 16 segments according to the Ameri-
an Heart Association model.18 Three representative short-axi
lices obtained at the level of the apex, midventricle, and base were
ivided into 4, 6, and 8 segments, respectively. The perfusion was
nalyzed in each segment.
eart Morphologic Study and Myocardial Histology
t the end of the study, the hearts were excised and sliced into 5
r 6 rings. Both sides of the slices were photographed. The infarct
rea and normal region of each slice were determined by using the
cion Image Analysis program. The percentage of infarction of the
hole LV wall was calculated.
The myocardial biopsy specimens were collected and frozen
mmediately. The tissues were serially sectioned at 5 m. The d
The Journal of Thoracicamples were stained with hematoxylin and eosin and for Factor
III to identify endothelial cells in the blood vessels. Both endo-
helial cells and vascular structure were evaluated by using fluo-
escent and confocal microscopy (PCM 2000, Nikon).
ecretion of Angiogenin in Gene-modified MSCs
portion of angiogenin-modified MSCs were collected from the
mplanted cell suspension. The cells were cultured for 8 days, and
he cultured media were collected for quantification of angiogenin
rotein levels by using enzyme-linked immunosorbent assay, ac-
ording to the manufacturer’s protocol. Media cultured with non-
ransfected MSCs were used as controls.
estern Blotting Analysis
t the end of the study, ventricular muscle was harvested adjacent
o the injection site for the evaluation of angiogenin protein levels.
he samples were homogenized in a lysis buffer and centrifuged at
2,000g for 10 minutes at 4°C. The supernatant was collected, and
rotein concentrations were measured. Total protein (40 g/lane)
as used for Western blot analysis with rabbit anti-angiogenin poly-
lonal IgG. Densitometry measurements were performed on digi-
ized images of the immunoprobed membranes by using Image-
uant software (Molecular Dynamics).
tatistical Analyses
ll results were presented as means  standard deviation. Con-
inuous variables (LVEF, FAC, regional wall thickening, LV in-
arction area, angiogenin expression, and blood vessel density) were
ompared with unpaired Student t tests (for comparison between 2
roups) or analysis of variance for comparison between multiple
roups. Comparison of angiographic collateral density through the
ollateral index was assessed by using 2-sided Kruskal-Wallis
multiple group comparison) and Wilcoxon rank sum (2 group
omparison) tests.
esults
n Vitro Studies
SCs (CD34/CD45) were cultured for transplantation.
low cytometric analysis showed that most cultured MSCs
xpressed CD44 (96.2%  1.2%). An adenoviral system
as used to deliver angiogenin into the MSCs with a trans-
ection efficiency of approximately 100%. MSCs from the
SCAdAng and MSCAdNull groups were cultured for 8 days
o quantify the secretion of angiogenin from the transfected
ells. The angiogenin protein level in the media cultured
ith MSCAdAng (1245  153 pg/mL) was significantly
reater (P  .001) than in the control media cultured with
SCAdNull (30  3 pg/mL).
n Vivo Studies
ight pigs died of an infection (MSCAdAng group, n  1;
SCAdNull group, n  2; AdAng group, n  3; AdNull
roup, n  2) and were therefore removed from the study.
Coronary angiography was performed at 28 days after
meroid implantation (Figure 1, A1-A4). There was n
ifference in angiographic (Rentrop) scores among the 4
and Cardiovascular Surgery ● Volume 132, Number 6 1331
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CSProups at this time point (P .783). However, 4 weeks after
ntramyocardial cell or gene implantation (Figure 1, B -B4),
entrop scores were significantly greater (P  .03 and
 .02, respectively) in the MSCAdAng group than in the
SCAdNull or AdAng groups, both of which displayed
igher scores (P  .001) than the AdNull group (Figure
and D).
Cardiac function was evaluated immediately before and
weeks after cell or gene implantation. Before treatment,
Figure 1. Angiography. A and B, Representative left
implantation (Pre-Tx) and 4 weeks after cell or gene im
stem cells (MSCs) infected with adenovirus containin
infected with null adenovirus (MSCAdNull, A2 and B2)
adenovirus alone (AdNull, A4 and B4). Before transplan
wall in all groups. After transplantation, myocardial
MSCAdAng group (B1), partially enhanced in the MSCA
AdNull group (B4) compared with pretransplantation
scores) were similar among the 4 groups before transpl
enhanced (P < .05) in the MSCAdAng group and partial
and remained unchanged in the AdNull group. D, T
significantly greater in the MSCAdAng group (P< .05) th
group displayed a decrease in this measure after treaVEF values were similar among the 4 groups. By 4 weeks t
332 The Journal of Thoracic and Cardiovascular Surgery ● Decfter treatment, LVEF values had decreased in the AdNull
roup but improved significantly in the genetically modified
ell–treated group (MSCAdAng) compared with all other
roups (P  .05). LVEF values did not differ significantly
etween the MSCAdNull and AdAng groups (Figure 2, A
nd B).
Echocardiographic assessment of FAC at the midven-
ricular level did not differ between the MSCAdAng group
nd the other groups before treatment. By 4 weeks after
nary angiographs conducted 4 weeks after ameroid
tation (Post-Tx) in pigs implanted with mesenchymal
angiogenin gene (MSCAdAng, A1 and B1), with MSCs
angiogenin alone (AdAng, A3 and B3), or with null
, ischemic areas were observed at the left ventricular
sion (arrows in B1-B4) was greatly enhanced in the
(B2) and AdAng (B3) groups, and not enhanced in the
ures. C, Left coronary angiographic scores (Rentrop
ion. After transplantation, these scores became greatly
hanced (P < .05) in the MSCAdNull and AdAng groups
osttransplantation increase in Rentrop scores was
the MSCAdNull and AdAng groups, whereas the AdNull
t. *P < .05.coro
plan
g the
, with
tation
perfu
dNull
meas
antat
ly en
he p
an in
tmenreatment, FAC increased significantly in the MSCAdAng,
ember 2006
CS
PFigure 2. Heart structure and function. A, Left ventricular ejection fraction evaluated by means of echocardiog-
raphy at 4 weeks after ameroid implantation (Pre-Tx) was similar among the 4 groups. Four weeks after cell or
gene implantation (Post-Tx), ejection fraction had increased significantly (P < .05) in the group implanted with
angiogenin gene–infected mesenchymal stem cells (MSCs; MSCAdAng group), remained unchanged in the groups
implanted with null adenovirus–infected MSCs (MSCAdNull group) or angiogenin (AdAng group), and decreased in
the group implanted with null adenovirus (AdNull group). B, The decrease in ejection fraction from before
transplantation to after transplantation was significantly greater (P < .05) in the MSCAdAng group than in the
MSCAdNull and AdAng groups, both of which showed greater change (P < .05) than in the AdNull group. C, Left
ventricular fractional area change measured before transplantation was similar among the 4 groups. After
transplantation, fractional area change significantly increased in the MSCAdAng, MSCAdNull, and AdAng groups but
was significantly greater in the MSCAdAng group compared with that in the control groups (P < .05). D, The
decrease in fractional area change from before transplantation to after transplantation was significantly greater
in the MSCAdAng group than in the MSCAdNull and AdAng groups, both of which showed greater change (P , .05)
than the AdNull group. E, Left ventricular wall thickness measured before transplantation was similar among the
4 groups. After transplantation, wall thickness had increased significantly (P< .05 for all groups) in the MSCAdAng,
MSCAdNull, and AdAng groups but had decreased in the AdNull group. F, The decrease in wall thickness from
before transplantation to after transplantation was greatest in the MSCAdAng group (P < .05 compared with all
other groups) and similar in the MSCAdNull and AdAng groups (P < .01 compared with the AdNull group). *P < .05,
**P < .01.
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CSPSCAdNull, and AdAng groups (P  .05) but was signifi-
antly greater in the MSCAdAng group than in the control
roups at this time point (Figure 2, C and D).
We found that genetically modified cell transplantation
MSCAdAng group) significantly increased regional wall
hickness at 4 weeks after cell or gene implantation (P .05
ompared with all other groups). Relative to the AdNull
roup, wall thicknesses in the MSCAdNull and AdAng
roups also increased significantly after cell or gene implan-
ation (P  .01; Figure 2, E and F).
Myocardial regional perfusion was evaluated with MRI.
he percentages of segments with abnormal perfusion im-
ediately before and 4 weeks after cell or gene implanta-
ion, respectively, were as follows: 32.3%  4.1% and
7.2%  2.1% in the MSCAdAng group, 29.7%  3.1%
nd 21.1%  2.0% in the MSCAdNull group, 27.7%  2.9%
nd 18.6%  1.9% in the AdAng group, and 32.1% 
.4% and 28.6%  2.9% in the AdNull group (Figure 3A
nd B). Animals that received genetically modified cells
MSCAdAng group) showed the greatest improvement in g
334 The Journal of Thoracic and Cardiovascular Surgery ● Decegional perfusion after treatment (P  .05 compared with
ll other groups). No significant difference was detected
etween the cell (MSCAdNull) and gene (AdAng) groups,
oth of which exhibited significantly improved perfusion
P  .05 for both groups) relative to the control (AdNull)
roup (Figure 3, C).
At the end of the study, hearts were harvested for mor-
hologic study. Lateral transmural infarctions were observed
n all hearts in every group (Figure 4, A-D). Histologic
xamination of the implanted myocardial region revealed
ngiogenesis in all groups at 4 weeks after cell or gene
reatment (Figure 4, E-H). Infarct sizes were smallest in 
SCAdAng group (P .05 compared with all other groups),
ith no significant difference between the MSCAdNull and
dAng groups, both of which displayed smaller infarct scars
P  .04 and P  .03, respectively) than the AdNull group
Figure 4, I). Vascular density was increased significan
ore in animals implanted with genetically modified cells
MSCAdAng group) than in those given cell (MSCAdNull
Figure 3. Myocardial perfusion. A and
B, Magnetic resonance imaging show-
ing myocardial perfusion at 4 weeks
after ameroid implantation (before trans-
plantation, A1-A4) and 4 weeks after
cell or gene treatment (after transplan-
tation, B1-B4) in pigs implanted with
angiogenin gene–infected mesenchymal
stem cells (MSCs; MSCAdAng group),
with null adenovirus-infected MSCs
(MSCAdNull group), with angiogenin
(AdAng group), or with null adenovirus
(AdNull group). There were significant
improvements after treatment in the
MSCAdAng (B1), MSCAdNull (B2), and
AdAng (B3) groups and no improve-
ment in the AdNull group (B4). C, From
before transplantation to after trans-
plantation, the change in the number of
abnormal perfusion segments was
greatest in the MSCAdAng group (P <
.05 compared with all other groups).
Decreases in this measure were simi-
lar in the MSCAdNull and AdAng groups
and smallest in the AdNull group (P <
.05 compared with the MSCAdNull and
AdAng groups). *P < .05.roup, P  .04) or gene therapy (AdAng group, P  .03)
ember 2006
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Plone but was also increased in the AdAng group relative
o the MSCAdNull (P  .05) and AdNull (P  .03) groups
Figure 4, J).
Cultured MSCs were labeled with DiI before transplan-
ation to confirm MSC engraftment to the implanted (isch-
mic) area. Labeling efficiency was 100% (Figure 5, A). Four
eeks after cell implantation, successful MSC engraftment
as confirmed in both MSC-treated groups (MSCAdAng and
SCAdNull group) by the appearance of DiI-labeled cells at
he site of implantation under fluorescence and confocal
icroscopy (Figure 5, B-E). A large number of DiI-label
Figure 4. Morphology and histology. A through D, Phot
after cell or gene implantation in pigs implanted with
MSCAdAng group, A), with null adenovirus-infected MSC
null adenovirus (AdNull, D). Lateral infarctions (arro
Microphotographs illustrating hematoxylin and eosin s
4 weeks after cell or gene implantation. Scale bars (E-H
group (P < .05 compared with all other groups) and lar
greatest in the MSCAdAng group (P < .05 compared wi
.05) blood vessels than the MSCAdNull and AdNull grouSCs were observed in the genetically modified cell– fi
The Journal of Thoracicreated group (MSCAdAng group). These implanted cells
ere observed in regions of necrotic myocardial tissue and
dhered to the collagen-rich matrix, although not in areas
emote to the injection site. Immunofluorescent staining for
actor VIII revealed that a significant portion of the im-
lanted MSCs (DiI positive) expressed Factor VIII and were
ncorporated into blood vessels in the ischemic myocardial
egions (Figure 5, F and G).
Angiogenin expression in the implanted area was quan-
ified by means of Western blot analysis. Animals treated
ith angiogenin (either through gene or genetically modi-
hs of left ventricular cross-sections taken at 4 weeks
genin gene–infected mesenchymal stem cells (MSCs;
SCAdNull, B), with angiogenin gene (AdAng, C), or with
in A-D) were observed in all groups. E through H,
ng in the infarcted myocardial tissue of each group at
200 m. I, the scar area was smallest in the MSCAdAng
in the AdNull group. J, Although vascular density was
other groups), the AdAng group exhibited more (P <
P < .05.ograp
angio
s (M
ws
taini
) 
gest
th all
ps. *ed cell therapy) displayed significantly greater angiogenin
and Cardiovascular Surgery ● Volume 132, Number 6 1335
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CSProtein expression in the implanted area than did non–gene-
reated groups (P  .05 for both groups, Figure 6).
iscussion
reclinical19,20 and clinical21 studies have demonstrated tha
ell transplantation can augment cardiac function when im-
lanted into the ischemic myocardium. Although the mech-
nisms responsible for this beneficial effect have not been
ully elucidated, the cells increase regional perfusion, main-
ain myocardial thickness, and prevent ventricular dilata-
ion, which can preserve function and delay heart failure.
In the present study we used ameroid occlusion to pro-
uce a pig model of chronic ischemia similar to the status of
atients presenting for coronary bypass surgery. The amer-
id constrictor results in reproducible and gradual occlusion
f the coronary artery with reduced blood flow to the lateral
ircumflex territory. This reduction in coronary flow leads
o a significant reduction in regional myocardial function
ith minimal myocardial necrosis.
We hypothesized that the synergistic effect of cell and
ene therapy would restore cardiac function in the ischemic
ardiomyopathic heart. We found that (1) implantation of
utologous MSCs overexpressing angiogenin into an isch-
mic myocardium model significantly improved LV func-
ion compared with angiogenin gene therapy or the implan-
ation of MSCs alone; (2) the autologous MSCs engrafted
uccessfully for at least 4 weeks after implantation into the
schemic myocardium, altered pathologic ventricular re-
odeling, and attenuated contractile dysfunction; and (3)
njection of the angiogenin gene in a viral vector into the
schemic myocardium resulted in high expression of angio-
enin in the myocardium at 4 weeks after gene injection,
hich stimulated excellent collateral vessel development.
owever, this treatment was less effective at improving
eart function than the delivery of the gene from the trans-
ected cells.
MSCs were used in the current study as the cell source
or combined cell and gene therapy for several reasons.
irst, MSCs possess pluripotential capabilities6 and have
een shown to improve heart function in animal studies8-10
urthermore, these cells are easily obtained from bone mar-
ow and can be expanded in culture.11 MSCs have been
sed as gene carriers in in vivo studies. For example, Duan
nd associates22 reported the transplantation of MSCs tran-
ected with hepatocyte growth factor gene into damaged
yocardial tissue in a rat model. In that study the growth
actor gene was overexpressed at the implanted area, and
ell and gene therapy improved cardiac function.
For this study, we selected angiogenin for transfection
nto MSCs destined for transplantation. Angiogenin is a
asic heparin-binding protein (14.4 kd)14 belonging to th
Nase superfamily, which shows 33% homology to ribo-igure 5. DiI and Factor VIII labeling in the myocardial transplan-
ation area. A, Twenty-four hours after labeling with DiI, 100% of
ultured mesenchymal stem cells (MSCs) were DiI positive under
he fluorescent microscope. B through E, Fluorescent and confo-
al micrographs showing myocardial transplant sites at 4 weeks
fter cell implantation in pigs implanted with angiogenin gene–
nfected MSCs (MSCAdAng group, B and C) or with null adenovirus-
nfected MSCs (MSCAdNull group, D and E). The presence of
iI-positive cells (arrows in B and D) indicated successful en-
raftment of MSCs in both groups. F and G, Confocal micrographs
howing Factor VIII staining at myocardial transplant sites in the
SCAdAng group. Some of the implanted cells were positive for
actor VIII (arrow in F) and were incorporated into blood vessels
arrow in G) in the ischemic regions. Scale bars: 100 m in A anduclease A.23 It is an angiogenic factor the expression of
ember 2006
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Phich is upregulated by hypoxia,24 giving it great potentia
or therapeutic angiogenesis.25 Human angiogenin has bee
ocalized to chromosome 14q11, proximal to the / T-cell
eceptor.23 Several studies have demonstrated that angiog-
in stimulates endothelial cell proliferation and promotes
he adhesion of endothelial cells and fibroblasts,26,27 en-
ancing neovascular formation. In vivo studies have further
hown that angiogenin stimulates collateral vessel develop-
ent in the ischemic myocardium of rabbit hearts.16 In the
resent study we found that an adenoviral vector containing
he angiogenin gene successfully infected the ischemic myo-
ardium after intramyocardial injection. Overexpressed in
he myocardium at the injected area, angiogenin stimulated
lood vessel formation, which increased regional perfusion
nd prevented the progress of heart failure in angiogenin-
reated animals (AdAng group) compared with control an-
mals (AdNull group).
In the animals receiving genetically modified cell trans-
lants (MSCAdAng group), we demonstrated that a synergis-
ic effect of implanted cells and gene expression contributed
igure 6. Angiogenin expression. A, Western blot analysis re-
ealed angiogenin protein bands in the myocardial tissues of
igs implanted with angiogenin gene–infected mesenchymal stem
ells (MSCs; MSCAdAng group), with null adenovirus-infected
SCs (MSCAdNull group), with angiogenin gene (AdAng group), or
ith null adenovirus (AdNull group). B, Quantitative analysis of
yocardial angiogenin protein expression, expressed as an in-
ex of the ratio of expression relative to AdNull group levels
100% expression in the AdNull group), indicated that angiogenin
rotein was expressed at greater levels in the groups that re-
eived angiogenin gene transfection (MSCAdAng and AdAng
roups, P < .05 for all groups) than in the nontransfected groups
MSCAdNull and AdNull groups). *P < .05.o the augmentation of cardiac function. To increase trans- u
The Journal of Thoracicection efficiency in the MSCs and gene expression in vivo
or these animals, we used an adenoviral vector containing
ngiogenin to transfect the cells. The transfection efficiency
as 100%, and Western blot data illustrated that angiogenin
as overexpressed in the ischemic myocardium for at least
weeks. However, the mechanism responsible for the ben-
ficial effect in combined angiogenin and MSC transplan-
ation and the relative benefits of angiogenin compared with
ther genes used to enhance cell transplantation (eg, insulin-
ike growth factor, hepatocyte growth factor, vascular en-
othelial growth factor, and hypoxia inducible factor 1
lpha) were not identified in this study. Future work will be
equired to determine the best enhancements to cell
ransplantation.
Using DiI as a marker, we observed engraftment of
ransplanted MSCs in the myocardium after cell implanta-
ion, and we suspect that the survival of engrafted cells was
reater in the group receiving genetically modified MSCs
han in the group receiving unmodified MSCs. However, we
id not perform a quantitative assessment of cell engraft-
ent, and future studies will need to quantitatively compare
ur strategy with other gene enhancements to determine the
est approach to augment cell engraftment after transplan-
ation.
MRI and coronary angiography detected significant col-
ateral vessel development at the lateral circumflex area
fter injection of genetically modified MSCs that overex-
ressed angiogenin. Echocardiographic and MRI results
urther suggested that the presence of these cells signifi-
antly improved functional measures. Alone, MSC implants
an induce angiogenesis in vivo because of their ability to
ecrete various angiogenic factors or cytokines.10,19 How-
ver, in this study the group receiving MSCs that overex-
ressed angiogenin demonstrated significantly greater an-
iogenic capacity than the group undergoing transplantation
ith untreated cells. The beneficial effect could have been
ue to angiogenesis, enhanced cell engraftment, or an inhi-
ition of the postinfarction remodeling.
Future studies will be required to determine the duration
f transfected gene expression in vivo, although gene ex-
ression has been documented to persist in transplanted
ells from 5 weeks to 1 year.20 Fortunately, even transien
ene expression might have lasting effects on angiogenesis,
ell engraftment, and the prevention of ventricular remod-
ling. Future studies will also determine the optimal number
f cells for implantation and the optimal dose of angiogenin
denovirus to compare the effectiveness of combination
herapy with that of cell or gene therapy under optimal
onditions.
In summary, the present study demonstrated that bone
arrow–derived MSC transplantation into the ischemic
yocardium improved cardiac function by altering ventric-lar remodeling and increased myocardial perfusion. How-
and Cardiovascular Surgery ● Volume 132, Number 6 1337
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CSPver, transplantation of MSCs overexpressing angiogenin
learly produced stronger beneficial effects on ventricular
odulation and the greatest increase in myocardial reper-
usion; the combined cell and gene treatment therefore
mproved cardiac function in a synergistic manner. We
uggest that treatments combining cell therapy with gene
herapy could be an effective strategy to restore cardiac
unction in chronic ischemia.
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